Vasopore, Inc. — SEC Form D Filing
Vasopore, Inc. filed an SEC Form D on October 28, 2026, reporting $1.10M raised in Medical Devices.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 28, 2026
- Amount reported
- $1.10M
- Round stage
- Seed
- Industry
- Medical Devices
- Website
- https://www.vasopore.com/
What the company does
Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Patients with vascular disease need safer, more effective, and durable minimally invasive treatment options.
Solution
Vasopore is developing an active intravascular drug delivery platform to enable safer, more durable, and more effective minimally invasive therapies.
Why now
Growing demand for targeted, device-based local pharmacotherapy to avoid systemic toxicity and improve outcomes in complex vascular interventions.
Verdict
This cleared because the multi-billion-dollar exits of drug-coated balloons and intravascular lithotripsy proved strategic acquirers pay massive premiums for interventional catheter upgrades, not because active drug delivery had been mechanically or clinically de-risked. Investors implicitly bet that active elution solves the acute drug-loss and tissue-penetration ceilings of passive balloons without adding deliverability friction in tortuous vessels. What capped upside was standard medtech capital intensity: a sub-two-million-dollar seed barely finances bench validation, exposing early equity to crushing dilution across subsequent clinical trials and PMA-track timelines.
Source: SEC EDGAR Form D filing